Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
Cenestra's research shows that there are clearly superior ratios and dosages of these bioactive lipids for specified applications.
Dec 8 2011 --- Cenestra Health announces that the U.S. Patent and Trademark Office (the "USPTO") has issued a new U.S. patent, No. 8,071,646 (the "'646 patent"), that protects and provides Cenestra with exclusivity for highly pure formulations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in ratios ranging from about 3.5:1 to about 5:1. The '646 patent provides exclusivity for these EPA:DHA ratios in compositions with > 84% omega-3s as the active ingredient. The '646 patent also provides exclusive rights to a number of uses for these superior EPA:DHA ratios.
While Cenestra's previously awarded U.S. patent No. 7,652,068 secured Cenestra's intellectual property on a composition of highly pure ethyl ester forms omega-3 formulations in EPA:DHA ratios of 4.1:1, the '646 patent greatly broadens the opportunity to develop highly unique and best in class EPA:DHA prescription products. Both patents place Cenestra in a unique position to have therapeutically superior, patent protected products for treatment of diseases such as cardiovascular disease and depression.
"We are pleased that the USPTO recognized the novelty of these specific ratios of EPA to DHA that Cenestra discovered. Cenestra's research shows that there are clearly superior ratios and dosages of these bioactive lipids for specified applications. We hope to bring Cenestra's innovative products to patients afflicted with the illnesses that these specific ratios of omega-3s are optimized to treat," said Louis Sanfilippo, M.D., Assistant Clinical Professor at Yale School of Medicine and Managing Director of Cenestra Health.
"We believe that with the granting of the '646 patent, Cenestra finds itself in the unique position as the only high purity omega-3 company with straight-forward composition patents with long patent life remaining. We believe this will allow Cenestra the ability to garner considerable investment in product development, and sales and marketing. From the data Cenestra has generated to date, we expect the products developed under the Cenestra patents will confer superior efficacy to those currently on the market or announced to be in development," stated Dr. Sanfilippo.
